News

The MPNs include essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). A total of 18 patients have been enrolled in this open-label, single-arm, multicenter Phase II

According to FDA, all currently enrolled patients can continue receiving aldoxorubicin treatment, or comparator drugs, as per study protocols. Additionally, the company cannot enrol new patients until the

The new liquid formulation eliminates the need of reconstituting lyophilized powder with sterile water before adding the required dose of medicine to the infusion bag and administering to

Created by Atlas Venture and Caribou Biosciences, together with leading scientists who have pioneered and shaped the field of CRISPR biology, Intellia leverages exclusive access to one of

The collaboration will focus on new therapeutic approaches for the treatment of various acute neurological conditions resulting from neurovascular instability. This discovery collaboration brings together Edge’s scientific expertise

"We are proud and hopeful to play a role to develop a treatment that could potentially reduce the rate of prosthesis abandonment for those who have so honorably

This invention is for a nanotechnology process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid nanosomes for use in combination therapy by means of Aphios’ SuperFluids technology

The territory covers China including Mainland China, Taiwan, Hong Kong and Macau as well as other countries, including Thailand, Brazil and Russia. 3SBio president and CEO Dr Jing

Harvoni is a combination of the NS5A inhibitor ledipasvir (LDV) and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) and is indicated to treat adults with chronic hepatitis C